GOVX · GeoVax Labs, Inc.

GeoVax’s 2025 financial results reflect a strategic pivot following the April 2025 termination of its BARDA/RRPV contract for convenience — a key driver behind the $3.5 million decline in government revenue and $5.6 million reduction in R&D expenses. The net loss improvement — from $25.0 million to $21.5 million — was achieved despite a $600K increase in G&A expenses, underscoring disciplined cost management amid pipeline prioritization. Management explicitly attributes the R&D decrease to discontinued costs tied to the terminated BARDA program and lower spending on GEO-CM04S1 and Gedeptin manufacturing and trials. Critically, the cash balance fell to $3.1 million at year-end — down 44% year-over-year — highlighting acute near-term liquidity constraints that will likely necessitate capital raising ahead of the planned Phase 3 initiation in late 2026. Operationally, the company secured formal Scientific Advice from the EMA validating an accelerated path for GEO-MVA: a single immuno-bridging Phase 3 trial without prior Phase 1/2 requirements, positioning it as a potential solution to global orthopoxvirus vaccine supply shortages. Supporting data from ongoing programs — including superior immune responses for GEO-CM04S1 in CLL patients and Gedeptin’s progression into combination strategies — reinforce technical credibility but do not offset the financial urgency signaled by the cash position. With no forward guidance disclosed in the press release or 8-K, investors must assess viability through upcoming clinical milestones and near-term financing execution.